A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies

Administered By

Duke Cancer Institute

Awarded By

Bristol-Myers Squibb Company

Contributors

Ready, Neal Edward Principal Investigator

Start/End

January 17, 2017 - October 31, 2021